Evidence map›Paper›PMID 34390283›Full record

Trial reportThe oncologist2021

Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.

Ting Bao, Raymond Baser, Connie Chen, Matthew Weitzman, Yi Lily Zhang, Christina Seluzicki, Qing Susan Li, Lauren Piulson, W Iris Zhi

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 11 pooled it
3.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 11 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. BeyondFrontiers in pain research (Lausanne, Switzerland) · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Article
  15. Symptoms experienced during the first 4 months of chemotherapy administration: a longitudinal cohort study in an Australian cancer treatment unit.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ting BaoIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-4437-2597
Raymond BaserDepartment of Epidemiology and Biostatics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Connie ChenDepartment of Medicine, New York University Winthrop Hospital, Mineola, New York, USA.
Matthew WeitzmanIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yi Lily ZhangIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Christina SeluzickiIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-8553-6810
Qing Susan LiIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lauren PiulsonIntegrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
W Iris ZhiBreast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Commack, New York, USA.ORCID 0000-0003-4263-7272
Memorial Sloan Kettering Cancer Center · USWinthrop-University Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT)TrialR37CA248563 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ting Bao · 2021 to 2026
$3.9M
Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) TrialR01CA251470 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BAO, TING · 2021 to 2025
$3.6M
Effect and Mechanism of Acupuncture for Cancer-related Cognitive Impairment (ENHANCE)R01CA240417 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MAO, JUN J · 2020 to 2024
$3.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA240417NCI NIH HHS R01 CA251470NCI NIH HHS R37 CA248563
6 · The paper itself

Abstract

backgroundChemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens the quality of life of cancer survivors. MATERIALS AND

methodsSurvivors of solid tumors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to 8 weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC). We previously reported the primary endpoint (NRS); here we report the following health-related quality of life endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI). For each endpoint, the mean changes from baseline and 95% confidence intervals were estimated within each arm and compared between arms using linear mixed models.

resultsWe enrolled 75 survivors of solid tumors with moderate-to-severe CIPN into the study. Compared with baseline, at week 8, FACT/GOG-Ntx, HADS anxiety, and ISI scores significantly improved in RA and SA, but not in UC. Compared with UC, at week 8, FACT/GOG-Ntx scores significantly increased in RA and SA arms indicating improved CIPN-related symptoms and quality of life (p = .001 and p = .01). There was no statistically significant difference between RA and SA. There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12.

conclusionAcupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN. Further large sample size studies are needed to delineate placebo effects. IMPLICATIONS FOR PRACTICE: The authors conducted a randomized sham acupuncture- and usual care-controlled clinical trial to evaluate the impact of acupuncture on health-related quality of life outcomes in patients with solid tumors with chemotherapy-induced peripheral neuropathy (CIPN). Statistically significant improvements in quality of life, anxiety, insomnia, and fatigue were achieved with 8 weeks of real acupuncture when compared with baseline, without statistically significant differences between real and sham acupuncture. These findings suggest that acupuncture may be effective for improving CIPN-related symptoms and quality of life and reducing anxiety and insomnia in cancer survivors with persistent CIPN, with further study needed to delineate placebo effects.

Indexed as

Acupuncture TherapyAntineoplastic AgentsCancer SurvivorsNeoplasmsPeripheral Nervous System DiseasesFemaleHumansQuality of LifeAntineoplastic AgentsAcupunctureAnxietyCancerInsomniaNeuropathyQuality of life

Identifiers

PMID34390283
PMCPMC8571772
OpenAlexW3193085598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.